Core Viewpoint - A class action securities lawsuit has been filed against Charter Communications, Inc. alleging securities fraud that adversely affected investors during a specific time frame [1][2]. Class Definition - The lawsuit represents all individuals and entities who purchased or acquired Charter securities, including call options and put options, between July 26, 2024, and July 24, 2025 [2]. Case Details - The complaint alleges that Charter Communications made false statements regarding the impact of the Affordable Connectivity Program (ACP) ending, which was not managed effectively by the Company [3] - It is claimed that the end of the ACP had a significant and sustained negative impact on Internet customer declines and revenue [3] - The Company reportedly failed to execute broader operations to compensate for the adverse effects of the ACP ending, leading to greater risks to business plans and earnings growth than disclosed [3] - The lawsuit asserts that the Company had no reasonable basis for its positive statements about its operations and long-term growth trajectory during the class period [3]. Next Steps - Investors who suffered losses during the relevant time frame have until October 14, 2025, to request appointment as lead plaintiff, although participation does not require this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securing compensation for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Snap Inc. ("Snap" or the "Company") (NYSE: SNAP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Snap investors who were adversely affected by alleged securities fraud between April 29, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/snap-inc-lawsuit-submission-form-2?prid=168 ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Lockheed Martin Corporation ("Lockheed Martin Corporation" or the "Company") (NYSE: LMT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lockheed Martin Corporation investors who were adversely affected by alleged securities fraud between January 23, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team: htt ...

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2] - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2] - The public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its expertise in complex securities litigation [4]

Core Viewpoint - V.F. Corporation is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between October 30, 2023, and May 20, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that V.F. Corporation made materially false and misleading statements regarding its turnaround plans, particularly concerning the Vans brand, which required significant reset actions to return to growth [2]. - Following the release of V.F. Corporation's fiscal 2025 results on May 21, 2025, it was revealed that Vans experienced a decline in revenue growth, with losses worsening from 8% to 20% in the fourth quarter [2]. - The company attributed its disappointing results to deliberate actions taken to eliminate unprofitable businesses, indicating that even without these actions, Vans would have shown a "high single digit" revenue decline [2]. Group 2: Stock Price Impact - On May 21, 2025, V.F. Corporation's stock price dropped from $14.43 to $12.15 per share, marking a decline of approximately 15.8% in one day following the negative news [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 12, 2025, to request appointment as lead plaintiff in the lawsuit, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, Briquilimab, which has resulted in significant stock price decline [1][2][3]. Group 1: Allegations and Issues - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which were necessary to ensure compliance with cGMP regulations [2]. - This lack of disclosure allegedly increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including Briquilimab [2]. - The failure to maintain proper controls also raised the likelihood of disruptive cost-reduction measures, leading to overstated business and financial prospects for the company [2]. Group 2: Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decrease, closing at $3.04 per share [3]. Group 3: Class Action Participation - Shareholders of Jasper Therapeutics may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action securities lawsuit has been filed against Flywire Corporation, alleging securities fraud that affected investors between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Flywire's revenue growth was overstated, and the negative impact of permit and visa-related restrictions on its business was understated [2]. - Defendants' public statements regarding Flywire were allegedly materially false and misleading throughout the relevant period [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 23, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, alleging that the company and its executives misled investors regarding its financial health and growth prospects, violating the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Liggett v. C3.ai, Inc., claims that C3.ai provided overly optimistic revenue projections while downplaying risks associated with CEO Thomas M. Siebel's health issues [2][3]. - The class period for the lawsuit is from February 26, 2025, to August 8, 2025, with a lead plaintiff deadline set for October 21, 2025 [2][4]. - Following a disappointing financial announcement on August 8, 2025, C3.ai's stock price dropped by more than 25% after the company lowered its revenue guidance for the fiscal year [3]. Group 2: Company Performance and Leadership Impact - C3.ai attributed its poor financial results to "reorganization with new leadership" and the health problems of CEO Thomas M. Siebel [3]. - The lawsuit emphasizes that C3.ai's public statements regarding growth and profitability were deemed "unrealistic" and overly reliant on Siebel's health and performance [2][5]. Group 3: Investor Actions - Investors who suffered significant losses during the class period are encouraged to submit their claims and may seek to serve as lead plaintiffs [2][4]. - The firm leading the investigation is focused on whether C3.ai's public statements adequately disclosed the impact of Siebel's health on the company's financial targets [5].

Group 1 - Halper Sadeh LLC is investigating PROS Holdings, Inc. for potential violations related to its sale to Thoma Bravo at $23.25 per share in cash [1] - Semler Scientific, Inc. is under investigation for its sale to Strive, Inc. for 21.05 Class A common shares of Strive per share of Semler [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation for securities fraud, following a significant drop in stock price after the company reported disappointing financial results for Q2 2025 [1][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Fluor securities between February 18, 2025, and July 31, 2025, with a deadline of November 14, 2025, to file a lead plaintiff motion [1][2]. - The lawsuit alleges that Fluor made materially false and misleading statements regarding its business operations and financial outlook during the class period [4]. Group 2: Financial Performance - On August 1, 2025, Fluor reported Q2 2025 financial results that missed consensus estimates, attributing the shortfall to rising costs from subcontractor design errors, price increases, and scheduling delays, along with reduced capital spending from clients [3]. - Following the announcement, Fluor's stock price fell by $15.35, or 27%, closing at $41.42 per share, which negatively impacted investors [3]. Group 3: Allegations Against Defendants - The complaint claims that the defendants failed to disclose significant adverse facts, including rising costs in key projects and the negative impact of economic uncertainty on the company's financial results [4]. - It is alleged that Fluor's financial guidance for FY 2025 was unreliable, and the effectiveness of its risk mitigation strategies was overstated [4].